{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:43Z","timestamp":1793346463296,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07962-8","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:07:49Z","timestamp":1790237269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Diabetes on Coronary Plaque Stabilization With Evolocumab: Insights From the YELLOW III Trial"],"prefix":"10.1007","author":[{"given":"Keisuke","family":"Yasumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Vengrenyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pruthvi C.","family":"Revaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Hooda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sweeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagat","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7189-3307","authenticated-orcid":false,"given":"Annapoorna S.","family":"Kini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"19","key":"7962_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570\u201381. https:\/\/doi.org\/10.1001\/jama.287.19.2570.","journal-title":"JAMA"},{"issue":"4","key":"7962_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","volume":"52","author":"SJ Nicholls","year":"2008","unstructured":"Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52(4):255\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2008.03.051.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7962_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10554-021-02297-x","volume":"38","author":"H Ueyama","year":"2022","unstructured":"Ueyama H, Yasumura K, Okamoto N, et al. Relationship between hemoglobin A1C and characteristics of plaque vulnerability in stable coronary disease: an optical coherence tomography study. Int J Cardiovasc Imaging. 2022;38(2):473\u201382. https:\/\/doi.org\/10.1007\/s10554-021-02297-x.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"9374","key":"7962_CR4","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC\/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(03)13636-7.","journal-title":"Lancet"},{"issue":"12A","key":"7962_CR5","doi-asserted-by":"publisher","first-page":"i56","DOI":"10.1016\/j.amjcard.2007.03.024","volume":"99","author":"HN Ginsberg","year":"2007","unstructured":"Ginsberg HN, Bonds DE, Lovato LC, et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):i56\u201367. https:\/\/doi.org\/10.1016\/j.amjcard.2007.03.024.","journal-title":"Am J Cardiol"},{"issue":"14","key":"7962_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"7962_CR7","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"issue":"2","key":"7962_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","volume":"394","author":"EA Bohula","year":"2026","unstructured":"Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2026;394(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2514428.","journal-title":"N Engl J Med"},{"issue":"16","key":"7962_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jama.2026.3277","volume":"335","author":"NA Marston","year":"2026","unstructured":"Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial. JAMA. 2026;335(16):1400\u20137. https:\/\/doi.org\/10.1001\/jama.2026.3277.","journal-title":"JAMA"},{"issue":"3","key":"7962_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1002358","volume":"364","author":"GW Stone","year":"2011","unstructured":"Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1002358.","journal-title":"N Engl J Med"},{"issue":"20","key":"7962_CR11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jacc.2020.09.547","volume":"76","author":"GW Stone","year":"2020","unstructured":"Stone GW, Maehara A, Ali ZA, et al. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque. J Am Coll Cardiol. 2020;76(20):2289\u2013301. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.547.","journal-title":"J Am Coll Cardiol"},{"issue":"10278","key":"7962_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","volume":"397","author":"D Erlinge","year":"2021","unstructured":"Erlinge D, Maehara A, Ben-Yehuda O, et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021;397(10278):985\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(21)00249-X.","journal-title":"Lancet"},{"issue":"18","key":"7962_CR13","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"JAMA"},{"issue":"7","key":"7962_CR14","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"14","key":"7962_CR15","doi-asserted-by":"publisher","first-page":"e009245","DOI":"10.1161\/JAHA.118.009245","volume":"7","author":"T Sugiyama","year":"2018","unstructured":"Sugiyama T, Yamamoto E, Bryniarski K, et al. Coronary plaque characteristics in patients with diabetes mellitus who presented with acute coronary syndromes. J Am Heart Assoc. 2018;7(14):e009245. https:\/\/doi.org\/10.1161\/JAHA.118.009245.","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"7962_CR16","doi-asserted-by":"publisher","first-page":"e031474","DOI":"10.1161\/JAHA.123.031474","volume":"12","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Niida T, Yuki H, et al. Coronary plaque characteristics and underlying mechanism of acute coronary syndromes in different age groups of patients with diabetes. J Am Heart Assoc. 2023;12(23):e031474. https:\/\/doi.org\/10.1161\/JAHA.123.031474.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"7962_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jcmg.2025.12.013","volume":"19","author":"AS Kini","year":"2026","unstructured":"Kini AS, Vengrenyuk Y, Liu JJ, et al. Intracoronary imaging and transcriptomic characteristics before and after maximum lipid-lowering therapy: YELLOW-III study of evolocumab and maximum statin therapy in chronic coronary disease. JACC Cardiovasc Imaging. 2026;19(4):516\u201334. https:\/\/doi.org\/10.1016\/j.jcmg.2025.12.013.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"7962_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/eurheartj\/ehp433","volume":"31","author":"F Prati","year":"2010","unstructured":"Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. 2010;31(4):401\u201315. https:\/\/doi.org\/10.1093\/eurheartj\/ehp433.","journal-title":"Eur Heart J"},{"issue":"12","key":"7962_CR19","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jacc.2011.09.079","volume":"59","author":"GJ Tearney","year":"2012","unstructured":"Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59(12):1058\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.079.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7962_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jacc.2016.10.028","volume":"69","author":"AS Kini","year":"2017","unstructured":"Kini AS, Vengrenyuk Y, Yoshimura T, et al. Fibrous cap thickness by optical coherence tomography in vivo. J Am Coll Cardiol. 2017;69(6):644\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2016.10.028.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7962_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jacc.2016.10.029","volume":"69","author":"AS Kini","year":"2017","unstructured":"Kini AS, Vengrenyuk Y, Shameer K, et al. Intracoronary imaging, cholesterol efflux, and transcriptomes after intensive statin treatment: the YELLOW II study. J Am Coll Cardiol. 2017;69(6):628\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2016.10.029.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"7962_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"7962_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"6","key":"7962_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","volume":"62","author":"RS Rosenson","year":"2019","unstructured":"Rosenson RS, Daviglus ML, Handelsman Y, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019;62(6):948\u201358. https:\/\/doi.org\/10.1007\/s00125-019-4856-7.","journal-title":"Diabetologia"},{"issue":"6","key":"7962_CR25","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/dom.13680","volume":"21","author":"AJ Lorenzatti","year":"2019","unstructured":"Lorenzatti AJ, Eliaschewitz FG, Chen Y, et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: primary results of the BERSON clinical trial. Diabetes Obes Metab. 2019;21(6):1455\u201363. https:\/\/doi.org\/10.1111\/dom.13680.","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"7962_CR26","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384. https:\/\/doi.org\/10.1001\/jama.2016.16951.","journal-title":"JAMA"},{"issue":"17","key":"7962_CR27","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","volume":"72","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72(17):2012\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.078.","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"7962_CR28","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1093\/eurheartj\/ehab433","volume":"42","author":"E Kedhi","year":"2021","unstructured":"Kedhi E, Berta B, Roleder T, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J. 2021;42(45):4671\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehab433.","journal-title":"Eur Heart J"},{"issue":"11","key":"7962_CR29","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.4244\/EIJ-D-23-00628","volume":"20","author":"D Del Val","year":"2024","unstructured":"Del Val D, Berta B, Roleder T, et al. Vulnerable plaque features and adverse events in patients with diabetes mellitus: a post hoc analysis of the COMBINE OCT-FFR trial. EuroIntervention. 2024;20(11):e707\u201317. https:\/\/doi.org\/10.4244\/EIJ-D-23-00628.","journal-title":"EuroIntervention"},{"issue":"2","key":"7962_CR30","doi-asserted-by":"publisher","first-page":"e014667","DOI":"10.1161\/CIRCINTERVENTIONS.124.014667","volume":"18","author":"RHJA Volleberg","year":"2025","unstructured":"Volleberg RHJA, Rroku A, Mol JQ, et al. FFR-negative nonculprit high-risk plaques and clinical outcomes in high-risk populations: an individual patient-data pooled analysis from COMBINE (OCT-FFR) and PECTUS-obs. Circ Cardiovasc Interv. 2025;18(2):e014667. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.124.014667.","journal-title":"Circ Cardiovasc Interv"},{"key":"7962_CR31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa072100","volume":"358","author":"R Detrano","year":"2008","unstructured":"Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336\u201345. https:\/\/doi.org\/10.1056\/NEJMoa072100.","journal-title":"N Engl J Med"},{"key":"7962_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIR.0000000000000228","volume":"132","author":"EP Havranek","year":"2015","unstructured":"Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132:873\u201398. https:\/\/doi.org\/10.1161\/CIR.0000000000000228.","journal-title":"Circulation"},{"issue":"10438","key":"7962_CR33","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(24)00413-6","volume":"403","author":"SJ Park","year":"2024","unstructured":"Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403(10438):1753\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(24)00413-6.","journal-title":"Lancet"},{"issue":"16","key":"7962_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1161\/CIRCULATIONAHA.124.070087","volume":"150","author":"P Libby","year":"2024","unstructured":"Libby P. Pathogenesis of atherothrombotic events: from lumen to lesion and beyond. Circulation. 2024;150(16):1217\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.070087.","journal-title":"Circulation"},{"issue":"6","key":"7962_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jcmg.2024.12.004","volume":"18","author":"R Vergallo","year":"2025","unstructured":"Vergallo R, Park SJ, Stone GW, et al. Vulnerable or high-risk plaque: a JACC: Cardiovascular Imaging position statement. JACC Cardiovasc Imaging. 2025;18(6):709\u201340. https:\/\/doi.org\/10.1016\/j.jcmg.2024.12.004.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9716","key":"7962_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(09)61965-6.","journal-title":"Lancet"},{"issue":"4","key":"7962_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","volume":"40","author":"L Da Dalt","year":"2019","unstructured":"Da Dalt L, Ruscica M, Bonacina F, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019;40(4):357\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehy357.","journal-title":"Eur Heart J"},{"issue":"2","key":"7962_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98\u2013107. https:\/\/doi.org\/10.1038\/nri2925.","journal-title":"Nat Rev Immunol"},{"key":"7962_CR39","doi-asserted-by":"publisher","first-page":"0365","DOI":"10.34133\/research.0365","volume":"7","author":"S Shrestha","year":"2024","unstructured":"Shrestha S, Lee YB, Lee H, et al. Diabetes primes neutrophils for neutrophil extracellular trap formation through trained immunity. Res (Wash D C). 2024;7:0365. https:\/\/doi.org\/10.34133\/research.0365.","journal-title":"Res (Wash D C)"},{"issue":"12","key":"7962_CR40","doi-asserted-by":"publisher","first-page":"e13640","DOI":"10.1111\/eci.13640","volume":"51","author":"S Ministrini","year":"2021","unstructured":"Ministrini S, Andreozzi F, Montecucco F, et al. Neutrophil degranulation biomarkers characterize restrictive echocardiographic pattern with diastolic dysfunction in patients with diabetes. Eur J Clin Invest. 2021;51(12):e13640. https:\/\/doi.org\/10.1111\/eci.13640.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"7962_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/cells9010231","volume":"9","author":"A Bonaventura","year":"2020","unstructured":"Bonaventura A, Vecchi\u00e9 A, Abbate A, Montecucco F. Neutrophil extracellular traps and cardiovascular diseases: an update. Cells. 2020;9(1):231. https:\/\/doi.org\/10.3390\/cells9010231.","journal-title":"Cells"},{"issue":"5028","key":"7962_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.1718038","volume":"254","author":"AR Huber","year":"1991","unstructured":"Huber AR, Kunkel SL, Todd RF 3rd, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science. 1991;254(5028):99\u2013102. https:\/\/doi.org\/10.1126\/science.1718038.","journal-title":"Science"},{"issue":"3","key":"7962_CR43","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/ijms25031504","volume":"25","author":"R Veluthakal","year":"2024","unstructured":"Veluthakal R, Esparza D, Hoolachan JM, et al. Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in T2D progression. Int J Mol Sci. 2024;25(3):1504. https:\/\/doi.org\/10.3390\/ijms25031504.","journal-title":"Int J Mol Sci"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07962-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:07:50Z","timestamp":1790237270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07962-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":43,"alternative-id":["7962"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07962-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol for the YELLOW III trial was approved by the Institutional Review Board at Mount Sinai Hospital, and the present post hoc analysis was conducted using de-identified data in accordance with institutional guidelines.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent prior to enrollment in the YELLOW III trial.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Mehran has received institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, Astra-Zeneca, Bayer, Biosensors, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe, Medtronic, Novartis Pharmaceuticals, OrbusNeich, Philips, Transverse Medical, and Zoll; has received personal fees from the American College of Cardiology, Boston Scientific, the California Institute for Regenerative Medicine, Cine-Med Research, Janssen, WebMD, and the Society for Cardiovascular Angiography and Interventions; has received consulting fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, Concept Medical, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, and Philips; holds equity (<1%) in Applied Therapeutics, Elixir Medical, STEL, and CONTROLRAD (spouse); has served as a scientific advisory board member for the American Medical Association; and has a spouse who has served as a scientific advisory board member for Biosensors (spouse). Dr Khera has received consulting or speaker fees from Medtronic, Edwards Lifesciences, Abbott Structural Heart, Eastend Medical, Terumo, and Zoll Medical; has served as a proctor for Medtronic, W.L.Gore & Associates and Abbott Structural Heart; and is also global principal investigator of a study funded by Teleflex (no compensation). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}